Small molecule · Inhibitor of Bruton's tyrosine kinase (BTK) · developed by Sanofi
Tolebrutinib is an orally bioavailable, brain-penetrant small molecule that selectively inhibits Bruton's tyrosine kinase (BTK), both peripherally and within the central nervous system. It blocks B-cell antigen receptor signaling and microglial inflammatory signaling. It is being studied in multiple sclerosis.
Summary written with AI from the sources listed at the end of this page.
Multiple Sclerosis
Updated Nov 1, 2026. Something wrong or missing? Report it on the SNY page.
See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SNY catalysts and pipeline →